CD38 is a molecule that can act as an enzyme, with NAD-depleting and intracellular
signaling activity, or as a receptor with adhesive functions. CD38 can be found expressed …

The membrane proteins CD38 and CD157 belong to an evolutionarily conserved family of
enzymes that play crucial roles in human physiology. Expressed in distinct patterns in most …

The presence or absence of somatic mutations in the expressed immunoglobulin heavy
chain variable regions (IgVH) of chronic lymphocytic leukemia (CLL) cells provides …

Select subsets of immune effector cells have the greatest propensity to mediate antitumor
responses. However, procuring these subsets is challenging, and cell-based …

Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme
CD38, a protein highly expressed on hematological malignant cells, including those in …

Evolving studies in models of transplant rejection, inflammatory bowel disease, and cancer,
among others, have implicated purinergic signaling in clinical manifestations of vascular …

Purpose: Daratumumab and its use in combination with other agents is becoming a new
standard of care for the treatment of multiple myeloma. We mechanistically studied how …

Background CD38 has been established as an important therapeutic target for multiple
myeloma (MM), for which two CD38 antibodies are currently approved—daratumumab and …

B-cell chronic lymphocytic leukemia (B-CLL) is a heterogenous disease with a highly
variable clinical course. Recent studies have shown that expression of the protein tyrosine …

Heterogeneity in the clinical behavior of patients with chronic lymphocytic leukemia (CLL)
makes it difficult for physicians to accurately identify which patients may benefit from an early …